This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Total lymphoid irradiation (TLI)—a technique developed at Stanford University Medical Center, California, originally for treatment of stage III Hodgkin's disease—is yielding such "encouraging" results in patients with intractable rheumatoid arthritis that its application to a broader range of autoimmune diseases and organ transplantation is now being investigated.
In a keynote address at the recent meeting of the American Society of Therapeutic Radiologists (ASTR) in Orlando, Fla, Henry S. Kaplan, MD, director of the Cancer Biology Research Laboratory at Stanford, said that although use of TLI for autoimmune disease is still very much investigational, it would appear, "based on our limited experience so far, that this will become a new treatment for patients with very far advanced and crippling autoimmune disease."
Still, he emphasized the experimental nature of this work, telling the audience: "We would be quite alarmed if there were any widespread move to adopt this as a treatment for
Korcok M. Arthritis patients get long-term help from total lymphoid irradiation. JAMA. 1983;249(1):9–10. doi:10.1001/jama.1983.03330250005001
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: